Skip to content

Inside Scailyte – Episode 5: Meet Daniel Schoener

Inside Scailyte – Episode 5: Meet Daniel Schoener

Inside Scailyte – Episode 5: Meet Daniel Schoener

Inside Scailyte – Episode 5: Meet Daniel Schoener

 “Inside Scailyte” – Unveiling the Minds Behind Our Success!

At Scailyte, we believe that our team members are the heart and soul of our company. Their expertise and dedication drive our mission forward every day. Today, we’re thrilled to present the latest installment of “Inside Scailyte,” our captivating video interview series that shines a spotlight on the incredible individuals who make up our team.

Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel’s strategic insights and industry expertise play a vital role in shaping our business initiatives and driving our growth. In this episode, Daniel shares his inspiring journey, his vision for the future of precision medicine, and the exciting projects he’s working on at Scailyte.

Stay tuned for the premiere of “Inside Scailyte – Episode 5” and continue to follow our series as we delve deeper into the diverse talents and stories that fuel our success.

We’re excited to share this journey with you! Make sure to follow our page to catch all the episodes.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News